Biotech Daily

Monday July 20, 2026

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH DOWN: PRESCIENT UP 10%; PROTEOMICS DOWN 11%**

*** IMRICOR FILES ALL DEVICES TO FDA**

*** ONCOSIL WINS SAUDI PANCREATIC CANCER DEVICE APPROVAL**

*** HYDRIX: REMEDY $3.4m ENDO-VASCULAR SURGICAL ROBOTS**

*** MICROBA: SYNLAB FOR EUROPE, LATIN AMERICA MICROBIOME TESTS**

*** LTR, STRIVE US ROXUS ERECTILE DYSFUNCTION SUPPLY**

*** SYNTARA 2nd PHASE Ib SNT-5505 BONE, BLOOD CANCER COHORT**

*** CLINUVEL EXPECTS NASDAQ ADS LISTING TODAY**

*** ENTROPY WINS SOUTH AFRICA FIBRO-MYALGIA PSILOCYBIN PATENT**

*** PAINCHEK APPOINTS KAREN HOLZBERGER CEO ON $553k PA**

MARKET REPORT

The Australian stock market slipped 0.06 percent on Monday July 20, 2026, with the ASX200 down 5.4 points to 8,791.3 points. Eleven of the Biotech Daily Top 40 companies were up, 22 fell and seven traded unchanged. All four Big Caps fell.

Prescient was the best, up 0.7 cents or 9.6 percent to 8.0 cents, with 1.15 million shares traded. 4D Medical climbed 7.2 percent; Botanix was up 4.0 percent; Amplia, Clinuvel, Emvision and Saluda were up more than three percent; Aroa and Avita rose more than two percent; with Imricor and Telix up by less than one percent.

Proteomics led the falls, down two cents or 11.4 percent to 15.5 cents, with 179,348 shares traded.

Both Impedimed and Syntara lost 8.33 percent; Cyclopharm, Dimerix, Racura and Resonance shed more than six percent; Lumos and Nova Eye fell more than four percent; Medical Developments and Optiscan were down more than three percent; Alcidion, Artrya, Compumedics, Paradigm and Resmed shed two percent or more; EBR, Imugene, Nanosonics and Polynovo lost one percent or more; with Cochlear, CSL, Mesoblast, Neuren, Orthocell and Pro Medicus down by less than one percent.

IMRICOR MEDICAL SYSTEMS

Imricor says it has filed for US Food and Drug Administration 510(k) clearance for its Navtrac and Navtrac-magnetic resonance (MR) steerable cardiac catheter introducers.
Earlier this year, Imricor said it had FDA 510(k) clearance for its Vision-magnetic resonance (MR) diagnostic catheter and Northstar 3-dimensional magnetic resonance imaging (MRI) mapping and guidance system (BD: Jan 18, 29, 2026).
Today, the company said its Navtrac and Navtrac-MR were steerable introducer sets, comprising a bi-directionally-steerable sheath and an associated vascular dilator, that introduced and guided a range of cardio-vascular catheters.
The company said the Navtrac had a standard dilator for use in x-ray catheterization laboratories, while the Navtrac-MR included a dilator containing magnetic resonance (MR) tracking coils for use in interventional magnetic resonance (IMR) laboratories.
Imricor said following the filings all its devices had been submitted to, or cleared by, the FDA, with 14 of 15 submissions completed for the commercialization of its full product platform in the US.
Imricor executive chair Steve Wedan said that “submitting the Navtrac family of steerable introducers completes our 510(k) filings and brings us another step closer to delivering our full platform to the US market”.
“It is a significant milestone for the entire Imricor family,” Mr Wedan said.
“The scale of what we are doing is extremely unusual and frankly, pretty impressive,” Mr Wedan said. “With 14 out of the 15 required submissions now with the FDA, we have filed more than 50,000 pages of product and regulatory documentation.”
“Enabling a transition from x-ray [catheterization laboratories] to IMR labs required all the tools and systems needed in the lab to be re-invented and developed for use with MRI, and it’s not often that such a multi-product portfolio is driven through approvals and to market all at the same time,” Mr Wedan said.
“In my 36 years of developing medical devices, I don’t recall ever seeing something as ambitious as this,” Mr Wedan said.
Imricor was up 2.5 cents or 1.5 percent to $1.66.

ONCOSIL MEDICAL

Oncosil says it has Saudi Arabia Food and Drug Authority approval for its radio-therapy device in unresectable, locally advanced pancreatic cancer.
Oncosil said eligible patients in Saudi Arabia could access its phosphorous-32 device through the Kingdom’s of Saudi Arabia’s reimbursement system, allowing patients to receive treatment without out-of-pocket cost.
The company said this removed “a significant barrier to access and supports broader adoption of the therapy across the country”.
Oncosil said the milestone was “a significant commercial achievement for Oncosil and opens access to one of the most important healthcare markets in the Middle East”.
Oncosil managing-director Nigel Lange said receiving Saudi approval was “an important step in our commercial expansion across the Middle East”.
“Saudi Arabia represents the largest healthcare market in the region, and this approval enables eligible patients to access our technology through the national reimbursement system without personal financial burden,” Mr Lange said.
“We also see significant potential for Saudi Arabia to serve as a regional referral hub, with patients from across the Gulf and the broader Middle East travelling to leading Saudi hospitals for advanced cancer treatment,” Mr Lange said.
Oncosil fell 15 cents or 10.3 percent to a post-consolidation $1.30.

HYDRIX

Hydrix says it has a $3.4 million contract with San Francisco's Remedy Robotics to develop software and electronics for endo-vascular intervention robotics.
Hydrix said the agreement continued its "international expansion strategy focused on delivering mission-critical medical technologies, including advanced robotics, [artificial intelligence]-enabled systems and Class II and III medical devices".
The company said Remedy Robotics was developing an artificial intelligence (A.I.)-enabled robotic platform, the N1 System, designed to allow clinicians to perform endo-vascular procedures with increased precision and remotely.
Hydrix said Remedy aimed "to radically expand access to specialist stroke and cardio-vascular intervention regardless of patient location", in partnership with its clinical partners including in Australia with the Australian Stroke Alliance; with revenue under the program to be recognized progressively in the year to June 30, 2027.
The company said the contract expanded its engineering support across Remedy's N1 system, including safety-critical software, embedded electronics, and verification-ready hardware input, to accelerate platform maturity ready for future clinical studies.
Hydrix managing-director Gavin Coote said the company's "experience developing complex regulated medical technologies supports clients developing next generation robotic and [artificial intelligence]-enabled medical systems".
Hydrix was unchanged at 0.4 cents with 9.3 million shares traded.

MICROBA LIFE SCIENCES

Microba says Munich's Synlab Group will distribute its microbiome diagnostics in Europe and Latin America for an initial three-year term with a further three-year option
Microba said it had been partnered with Synlab since 2020 and the original agreement included the distribution of its legacy Insight test under Synlab's Mybiome brand.
The company said the agreement took the partnership to its next-generation, clinical-grade, Microbiome Explorer platform "laying the foundation for a next phase of growth for the partnership"; with Microbiome Explorer testing included on Synlab's systems.
The company said Synlab would "manage local distribution and logistics, with Microba providing laboratory processing and report delivery".
Microba was unchanged at 4.4 cents.

LTR PHARMA

LTR says Strive Specialties Inc will manufacture, compound and supply Roxus for erectile dysfunction in the US.
Last month, LTR said it had a two-year agreement with the Pheonix, Arizona-based Strive to supply Roxus at US pharmacies (BD: Jun 11, 2026).
Last week, the company said it had a commercial agreement with Salt Lake City, Utah's Shed Holdings for the US telehealth distribution of Roxus (BD: Jul 17, 2026).
Today, LTR said that, with the Shed agreement, it had "in place the two core commercial pillars required for launch, patient acquisition and prescribing through telehealth, and national manufacturing and fulfilment through Strive Pharmacy".
The company said with Strive it would "focus on technology transfer, commercial inventory planning, manufacturing readiness and operational implementation ahead of … launch".
Previously, the company said it was developing Roxus, a nasal spray based on vardenafil, market by Bayer as Levitra, for erectile dysfunction (BD: Mar 26, 2025).
LTR fell half a cent or one percent to 50.5 cents.

SYNTARA

Syntara says it has safety approval to dose the second dose-escalation cohort in phase Ib of its 40-patient, phase Ib/II trial SNT-5505 for bone and blood cancer.
Last year, Syntara said it began an up-to 40-patient, phase Ib/II study of SNT-5505, or amsulostat, with 5-azacitidine (5-AZA) for myelodysplastic neoplasms and chronic myelomonocytic leukaemia (BD: Jul 18, 2025).
At the time, the company said phase Ib of the trial would enrol three-to-12 patients to assess the safety and recommended twice daily, oral dose of either 150mg or 200mg of SNT-5505, followed by a 30-patient phase II to study safety and efficacy endpoints.
Today, Syntara said that following review of the safety data from the first 150mg dose cohort, the independent drug safety monitoring board approved escalation to 200mg, with patients receiving SNT-5505 with the hypo-methylating agent 5-AZA.
The company said that “no dose-limiting toxicities were observed [in the 150mg cohort] and no new adverse events attributable to amsulostat were reported”.
Syntara said subject to completion of the 200mg cohort and review of the associated safety data, the study was expected to progress to a phase II component designed to evaluate the safety and efficacy of the selected dose in about 30 patients.
The company did not disclose the number of patients dosed in the 150mg phase Ib cohort, nor the number of patients expected to be dosed at the 200mg dose level.
Syntara said preliminary results from the phase Ib dose-escalation component were expected by 2027, with all 10 participating clinical sites in Germany recruiting.
Syntara fell 0.2 cents or 8.3 percent to 2.2 cents.

CLINUVEL PHARMACEUTICALS

Clinuvel says it expects its American depository shares (ADSs) to begin trading on the Nasdaq later today under the ticker symbol ‘CUVL’.
Last year, Clinuvel said it would upgrade its level I American depository receipts (ADRs), currently trading over-the-counter in the US, to a level II listing on the Nasdaq, with its primary listing on the ASX remaining unchanged (BD: Aug 22, 2025).
Later, the company said “the ongoing US Federal Government shutdown will impact timelines for review and approval” of its level II Nasdaq listing (BD: Nov 3, 2025).
In April, Clinuvel said it expected the US Securities and Exchange Commission (SEC) to complete the review of its draft registration statement for a Nasdaq uplisting from Level I to Level II, by July 2026 (BD: Apr 28, 2026).
Today, the company said the Nasdaq provided “greater visibility among US investors”.
Clinuvel was up 32 cents or 3.2 percent to $10.24 with 228,900 shares traded.

ENTROPY NEURODYNAMICS (FORMERLY TRYPTAMINE THERAPEUTICS)

Entropy says it has been granted a South African patent covering the methods of treating fibromyalgia using psilocybin.
Entropy said the patent, titled ‘Methods of Treating Fibromyalgia with Compositions Comprising Psilocybin’ would protect its intellectual property until September 2043.
The company said the patent provided “broad protection spanning treatment methods, dosing regimens, patient selection, clinical protocols, biomarkers, outcome measures and manufacturing”.
Entropy said fibro-myalgia was a chronic pain disorder characterized by widespread Musculo-skeletal pain, fatigue, sleep disturbance and cognitive impairment.
Entropy fell 0.05 cents or 1.4 percent to 3.55 cents.

PAINCHEK

Painchek says it has appointed Karen Holzberger as its chief executive officer, effective from August 17, 2026, with a salary of $US387,000 ($A553,000) a year.

Earlier this month, Painchek said in “a planned transition” Mr Daffas would cease as managing-director, with chief operating officer Andy Hoggan to act as interim chief executive officer until a replacement was appointed (BD: Jul 7, 2026).

Today, the company said the US-based Ms Holzberger had 26 years of healthcare leadership experience, had been Spintech MRI chief executive officer and had worked for Nuance Healthcare and GE Healthcare.

Painchek said Ms Holzberger held a Bachelor of Science from the Hoboken, New Jersey-based Stevens Institute of Technology.

The company said Ms Holzberger would be paid $US387,000 a year and was eligible for undisclosed short-term and long-term incentives.

Painchek fell half a cent or 4.8 percent to 10 cents.